JCB logo
BioLegend: Antibody Reagents
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published 3 September 2001. doi:10.1083/jcb.200103111
This Article
Right arrow Full Text
Right arrow PDF (Full Text)
Right arrow PPT slides of all figures
Right arrow Correction (v155,p859)
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JCB
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Xu, J.
Right arrow Articles by Brooks, P. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xu, J.
Right arrow Articles by Brooks, P. C.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Cancer
Related Collections
Right arrowRelated Article
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
© The Rockefeller University Press, 0021-9525/2001/9/1069 $5.00
The Journal of Cell Biology, Volume 154, Number 5, September 3, 2001 1069-1080


Article

Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo

Jingsong Xu1, Dorothy Rodriguez1, Eric Petitclerc1, Jenny J. Kim1, Masanori Hangai2, S. Moon Yuen2, George E. Davis3 and Peter C. Brooks1

1 Departments of Radiation Oncology and Cell Biology, Kaplan Cancer Center, New York University School of Medicine, New York, NY 10016
2 Department of Ophthamology, Doheny Eye Institute, University of Southern California, Los Angeles, CA 90033
3 Department of Pathology and Laboratory Medicine, Texas A & M University Health Science Center, College Station, TX 77843

Address correspondence to Peter C. Brooks, Departments of Radiation Oncology and Cell Biology, Kaplan Cancer Center, Rusk Building Room 806, New York University School of Medicine, 400 East 34th St., New York, NY 10016. Tel.: (212) 263-3021. Fax: (212) 263-3018. E-mail: peter.brooks{at}med.nyu.edu

Evidence is provided that proteolytic cleavage of collagen type IV results in the exposure of a functionally important cryptic site hidden within its triple helical structure. Exposure of this cryptic site was associated with angiogenic, but not quiescent, blood vessels and was required for angiogenesis in vivo. Exposure of the HUIV26 epitope was associated with a loss of {alpha}1ß1 integrin binding and the gain of {alpha}vß3 binding. A monoclonal antibody (HUIV26) directed to this site disrupts integrin-dependent endothelial cell interactions and potently inhibits angiogenesis and tumor growth. Together, these studies suggest a novel mechanism by which proteolysis contributes to angiogenesis by exposing hidden regulatory elements within matrix-immobilized collagen type IV.

Key Words: angiogenesis; ECM; cryptic sites; tumor; migration


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article

Collagen reveals a hidden talent
Alan W. Dove
J. Cell Biol. 2001 154: 902. [Full Text] [PDF]



This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents